试剂
过程开发
化学
异丙基
药品
组合化学
药物开发
异丙醇
产量(工程)
色谱法
柱色谱法
过程(计算)
前列腺素
高效液相色谱法
可扩展性
计算机科学
生化工程
药物输送
药物发现
药物靶点
作者
Zhongyu Liu,Lixia Qin,Manru Wang,Fangfang Liu,郭孟璧,Yitong Wang,Zhuang Hou,Chun Guo
标识
DOI:10.1021/acs.oprd.6c00330
摘要
Abstract Omidenepag isopropyl (OMDI) is the only marketed antiglaucoma drug that acts as a prostaglandin E receptor 2 (EP2) agonist. It exhibits high receptor-binding affinity (Ki = 3.6 nM) and potent agonistic activity (EC50 = 8.3 nM). More importantly, OMDI circumvents key limitations commonly associated with prostaglandin analogues, such as periorbital fat atrophy, hyperpigmentation, and drug tolerance, thereby offering greater clinical application value. However, the three previously reported synthetic routes to OMDI suffer from limitations that affect efficiency and scalability; for example, the isolated yields of routes I–III range from 20.5 to 51.2%. All of these routes involve the use of hazardous reagents (e.g., sodium hydride, borane) and often rely on column chromatography purification, which compromises material efficiency and process scalability. To address these issues, we report four new synthetic routes to OMDI developed through iterative optimization that systematically overcome the aforementioned limitations. Among them, route IV (accomplished in only four steps) avoids the use of high-hazard reagents and requires no column chromatography throughout the entire process, ultimately affording an improved overall isolated yield of 64.2% with 99.86% high-performance liquid chromatography (HPLC) purity. Notably, this process has been successfully validated on a hundred-gram scale, providing a reliable foundation for pilot-scale translation and potential industrial application.
科研通智能强力驱动
Strongly Powered by AbleSci AI